beta-Adrenergic antagonists with multiple pharmacophores: persistent blockade of receptors. 1983

J Pitha, and J Milecki, and T Czajkowska, and J W Kusiak

beta-Adrenergic antagonists containing from one to four identical pharmacophores were prepared and studied. These compounds had the general structure R2NCH(CH3)CH2[-OCH2CH(CH3)-]2-8NR2, where R is either H or an aryl-OCH2CHOHCH2 group. Synthesis was achieved by reaction of aryl glycidyl ethers with Jeffamines, which are primary diamines used in the manufacture of plastics. The following aryl groups were used: 2-allyphenyl, 4-(2-methoxyethyl)phenyl, 1-naphthyl, and 4-methoxyphenyl. The first three correspond to moieties of the established drugs alprenolol, metoprolol, and propranolol, respectively. The affinities of these compounds for beta-adrenergic receptors of rat heart and lung were estimated by measuring their ability to compete with the specific binding of (-)-[3H]-dihydroalprenolol. Compounds containing one pharmacophore bound to the receptors with affinities comparable to those of the parent drugs and the blockade of receptors could be dissociated by successive washes as easily as were those of the parent drugs. Compounds containing two or three pharmacophores had somewhat lower affinities for receptors, but the resulting blockade was persistent even after successive washing.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004082 Dihydroalprenolol Hydrogenated alprenolol derivative where the extra hydrogens are often tritiated. This radiolabeled form of ALPRENOLOL, a beta-adrenergic blocker, is used to label the beta-adrenergic receptor for isolation and study. 1-((Methylethyl)amino)-3-(2-propylphenoxy)-2-propanol
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

J Pitha, and J Milecki, and T Czajkowska, and J W Kusiak
September 1983, Journal of autonomic pharmacology,
J Pitha, and J Milecki, and T Czajkowska, and J W Kusiak
November 1960, The Journal of pharmacology and experimental therapeutics,
J Pitha, and J Milecki, and T Czajkowska, and J W Kusiak
September 1975, Biochemical pharmacology,
J Pitha, and J Milecki, and T Czajkowska, and J W Kusiak
February 1988, Postgraduate medicine,
J Pitha, and J Milecki, and T Czajkowska, and J W Kusiak
January 1981, Advances in cyclic nucleotide research,
J Pitha, and J Milecki, and T Czajkowska, and J W Kusiak
June 1987, The Journal of pharmacology and experimental therapeutics,
J Pitha, and J Milecki, and T Czajkowska, and J W Kusiak
November 1967, Schweizerische medizinische Wochenschrift,
J Pitha, and J Milecki, and T Czajkowska, and J W Kusiak
May 1967, Wiener klinische Wochenschrift,
J Pitha, and J Milecki, and T Czajkowska, and J W Kusiak
March 1986, Biochemical pharmacology,
J Pitha, and J Milecki, and T Czajkowska, and J W Kusiak
March 1984, Biochemical pharmacology,
Copied contents to your clipboard!